ClinicalTrials.gg
RecruitingNCT05465252OMEGA-AMDUpdated Jan 2, 2026

Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression

An interventional study of Krill Oil and Olive Oil in Age-Related Macular Degeneration, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
69th of 91
24 · median 62
Started
2025
with 14 others
No phase
12 of 107
6 open now
Primary completion
2026-03
later than 13 of 42 live
Registered
55th of 107
by date
Lead sponsor
5 of 107
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Among the 107 studies in Macular Degeneration with a site in China, this one is the 69th largest by planned enrollment of the 91 interventional ones that give a count, is one of 15 that started in 2025, is one of 12 with no phase, reaches primary completion later than 13 of the 42 other live ones, and was the 55th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD). Participants will receive 4 capsules of krill oil or placebo daily for a period of 3 months. Outcomes will be evaluated after 3-month treatment to assess differences between the two study groups.

03

Conditions studied

  • Age-Related Macular Degeneration

Keywords

  • dry age-related macular degeneration
  • krill oil
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults diagnosed with dry AMD at an early or intermediate stage, classified according to the Beckman Classification and confirmed by fundus photography: (1) Early AMD: medium drusen (>63 μm and ≤125 μm) without AMD-related pigmentary abnormalities; (2) Intermediate AMD: large drusen (>125 μm), with or without AMD-related pigmentary abnormalities.
  • Willing to stop supplementation of omega-3 fatty acids, choline, or astaxanthin.
  • Willing to sign the , and willing to attend follow-up visits for at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • Any eye with disease that would interfere with the fundus examinations.
  • Eye with choroidal neovascularization (CNV), geographic atrophy (GA), or high myopia.
  • Surgeries that may interfere with AMD evaluation.
  • Long-term use of any medications that are associated with retinal or neural toxicities.
  • History of supplementation with lutein, zeaxanthin, DHA, or EPA, unless a of at least 8 weeks is completed prior to enrollment.
  • Intraocular pressure more than 26 mmHg.
  • Received cataract surgery in 3 months.
  • Other conditions: subjects with severe systemic diseases; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the current visit plan; taking other angiogenesis Inhibitors drugs for treating cancer.
  • Other conditions not suitable for the current study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    krill oil

    Dietary Supplement: Krill Oil

  • Placebo comparator
    olive oil

    Dietary Supplement: Olive Oil

Interventions

  • Dietary supplementKrill Oil

    Qualified subjects start to take supplementation from Day 1 in the trial. Specifically, subjects from Intervention group take 4 capsules of krill oil per day.

    Also known as: Superba Boost

  • Dietary supplementOlive Oil

    Qualified subjects start to take placebo from Day 1 in the trial. Specifically, subjects from placebo group take 4 capsules of olive oil, which has the same color and smell as the krill oil.

06

What researchers measure

Primary outcomes

  1. Change in Macular Drusen Volume

    Macular drusen volume will be quantified using spectral-domain optical coherence tomography (SD-OCT). Automated segmentation of Bruch's membrane and the retinal pigment epithelium (RPE), followed by manual verification, will be performed to calculate drusen volume at baseline and after 3 months of intervention at the same retinal location. Change in macular drusen volume will be defined as the percentage change from baseline, calculated as the difference between post-intervention and baseline drusen volume divided by the baseline drusen volume.

    Time frame: From enrollment to the end of follow-up at 3 months.

Secondary outcomes

  1. Change in Maximum Macular Drusen Height

    Maximum macular drusen height will be measured using SD-OCT at baseline and after 3 months of intervention. Change in maximum macular drusen height will be defined as the percentage change from baseline, calculated as the difference between post-intervention and baseline maximum drusen height divided by the baseline maximum drusen height.

    Time frame: From enrollment to the end of follow-up at 3 months.

  2. Change in Best-Corrected Visual Acuity

    Best-corrected visual acuity (BCVA) will be assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and quantified as the total number of letters correctly identified by the participant. Change in BCVA will be defined as the absolute change in ETDRS letters from baseline, calculated as the difference between post-intervention and baseline measurements.

    Time frame: From enrollment to the end of follow-up at 3 months.

  3. Change in Self-Reported Visual Function

    Self-reported visual function will be assessed using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25). Change in self-reported visual function will be defined as the absolute change in NEI VFQ-25 total score from baseline, calculated as the difference between post-intervention and baseline scores.

    Time frame: From enrollment to the end of follow-up at 3 months.

07

Study locations

1 of 1 sites recruiting
  • Shanghai General Hospital, Shanghai Jiao Tong University
    Shanghai, 200080, China
    Recruiting
    • Xiaodong Sun · Contact+86-02163240090
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2026, 5 months after the start.

Of 105 non-industry interventional studies with no phase under Macular Degeneration, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 5 months is below that.

Counting every sponsor, half of 133 studies reached it within 37 months; a quarter within 17 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2022
First posted
Jul 19, 2022
StartActual
Oct 17, 2025
Primary completionEst.
Mar 2026
CompletionEst.
May 2026
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05465252
Responsible party
Xiaodong Sun (Professor, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Jul 19, 2022
Start date
Oct 17, 2025
Primary completion
Mar 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Jan 2, 2026

Study contacts

Huixun Jia, PhD
Contact
jiahuixun@163.com
+86 18017317575
Jiayu Xu
Contact
xujy_plusuuu@sjtu.edu.cn
+86 18516200956
Xiaodong Sun, PHD
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Krill oil

Start the discussion